Targeting specific proteins to improve treatment for inflammatory bowel disease
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD
['FUNDING_OTHER'] · AVIARA PHARMACEUTICALS, INC. · NIH-10871890
This study is looking at a new way to treat inflammatory bowel disease (IBD), like Crohn's Disease and Ulcerative Colitis, by focusing on a specific target in the body to help those who haven't had success with current treatments, and if you join, you might get access to new therapies that could make you feel better in the long run.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | AVIARA PHARMACEUTICALS, INC. (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10871890 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new treatment strategy for inflammatory bowel disease (IBD), which includes conditions like Crohn's Disease and Ulcerative Colitis. The approach aims to selectively target high affinity alpha4 integrins, which may lead to better treatment outcomes for patients who do not respond to existing therapies. By investigating the mechanisms behind treatment resistance, the research seeks to enhance the effectiveness and safety of IBD treatments. Patients participating in this research may receive novel therapies that could improve their long-term health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with moderate to severe inflammatory bowel disease who have not responded to current standard treatments.
Not a fit: Patients with mild forms of inflammatory bowel disease or those who have not been diagnosed may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients suffering from inflammatory bowel disease.
How similar studies have performed: Previous research has shown promise in targeting integrins for treating inflammatory conditions, indicating potential for success in this novel approach.
Where this research is happening
HOUSTON, UNITED STATES
- AVIARA PHARMACEUTICALS, INC. — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WOODSIDE, DARREN G — AVIARA PHARMACEUTICALS, INC.
- Study coordinator: WOODSIDE, DARREN G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.